|
06.02.2024 19:43:42
|
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 6 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 818.66 | 35 shares | |||||
| d) | Aggregated information
| 35 shares DKK 818.66 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (AQEA) AQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD) | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 801.37 | 309 shares | |||||
| d) | Aggregated information
| 309 shares DKK 801.37 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (AQEU) AQUIS EXCHANGE EUROPE | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 808.08 | 8,510 shares | |||||
| d) | Aggregated information
| 8,510 shares DKK 808.08 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (BEUP) CBOE EUROPE - DXE PERIODIC (NL) | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 805.90 | 355 shares | |||||
| d) | Aggregated information
| 355 shares DKK 805.90 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (CEUD) CBOE EUROPE - DXE DARK ORDER BOOK (NL) | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 811.02 | 35,585 shares | |||||
| d) | Aggregated information
| 35,585 shares DKK 811.02 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (CEUX) CBOE EUROPE - DXE ORDER BOOKS (NL) | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 810.89 | 3,962 shares | |||||
| d) | Aggregated information
| 3,962 shares DKK 810.89 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (MCSE) Nasdaq COPENHAGEN A/S - AUCTION ON DEMAND | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 818.83 | 159 shares | |||||
| d) | Aggregated information
| 159 shares DKK 818.83 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (SGMV) SIGMA X EUROPE AUCTION BOOK | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 820.50 | 26 shares | |||||
| d) | Aggregated information
| 26 shares DKK 820.50 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (TQEA) TURQUOISE EUROPE - LIT AUCTIONS | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 808.69 | 574 shares | |||||
| d) | Aggregated information
| 574 shares DKK 808.69 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (TQEX) TURQUOISE EUROPE | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 809.76 | 129,916 shares | |||||
| d) | Aggregated information
| 129,916 shares DKK 809.76 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (XCSE) NASDAQ COPENHAGEN A/S | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 807.51 | 569 shares | |||||
| d) | Aggregated information
| 569 shares DKK 807.51 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | (XPAC) POSIT AUCTION | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Amendment to company announcement no. 8 / 2024 which erroneously stated 10,000 shares too many, cf. also Remuneration Report 2023, page 20 | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with Long Term incentive programme) | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 0.00 | 139,422 shares | |||||
| d) | Aggregated information
| 139,422 shares DKK 0.00 | ||||
| e) | Date of the transaction | 2024-01-31 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 797.80 | 16,000 shares | |||||
| d) | Aggregated information
| 16,000 shares DKK 797.80 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Tania Sabroe | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 797.10 | 21,264 shares | |||||
| d) | Aggregated information
| 21,264 shares DKK 797.10 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 809.71 | 36,392 shares | |||||
| d) | Aggregated information
| 36,392 shares DKK 809.71 | ||||
| e) | Date of the transaction | 2024-02-06 | ||||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 809.64 | 74,915 shares | |||||
| d) | Aggregated information
| 74,915 shares DKK 809.64 | ||||
| e) | Date of the transaction | 2024-02-05 | ||||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Sale of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 823.09 | 60,000 shares | |||||
| d) | Aggregated information
| 60,000 shares DKK 823.09 | ||||
| e) | Date of the transaction | 2024-02-06 | ||||
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Elizabeth DeLuca (US) +1 609 580 9868 edel@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
| David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US)
+1 848 213 3219 mjhr@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com |
Company Announcement No 11 / 2024
Attachment
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordiskmehr Nachrichten
|
15:59 |
Starker Wochentag in Europa: So bewegt sich der STOXX 50 am Donnerstagnachmittag (finanzen.at) | |
|
12:27 |
STOXX 50 aktuell: STOXX 50 fällt mittags zurück (finanzen.at) | |
|
09:29 |
Börse Europa: STOXX 50 beginnt die Sitzung weit in der Verlustzone (finanzen.at) | |
|
20.11.24 |
Börse Europa: STOXX 50 zum Handelsende leichter (finanzen.at) | |
|
20.11.24 |
Verluste in Europa: STOXX 50 am Mittwochnachmittag mit Abgaben (finanzen.at) | |
|
20.11.24 |
STOXX 50 aktuell: So bewegt sich der STOXX 50 mittags (finanzen.at) | |
|
20.11.24 |
STOXX-Handel: STOXX 50 beginnt Handel in der Gewinnzone (finanzen.at) | |
|
19.11.24 |
Schwacher Wochentag in Europa: STOXX 50 zum Ende des Dienstagshandels in Rot (finanzen.at) |
Analysen zu Novo Nordiskmehr Analysen
| 18.11.24 | Novo Nordisk Neutral | UBS AG | |
| 15.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 13.11.24 | Novo Nordisk Neutral | UBS AG | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 11.11.24 | Novo Nordisk Neutral | UBS AG |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.